Transcatheter aortic valve implantation (TAVI) is a less invasive alternative to surgical aortic valve replacement (SAVR) for patients with symptomatic severe aortic stenosis (AS) and a high operative risk. Risk stratification plays a decisive role in the optimal selection of therapeutic strategies for AS patients. The accuracy of contemporary surgical risk algorithms for AS patients has spurred considerable debate especially in the higher risk patient population. Future trials will explore TAVI in patients at intermediate operative risk. During the design of the SURgical replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial, a novel concept of risk stratification was proposed based upon age in combination with a fixed number of predefined risk factors, which are relatively prevalent, easy to capture and with a reasonable impact on operative mortality. Retrospective application of this algorithm to a contemporary academic practice dealing with clinically significant AS patients allocates about one-fourth of these patients as being at intermediate operative risk. Further testing is required for validation of this new paradigm in risk stratification. Finally, the Heart Team, consisting of at least an interventional cardiologist and cardiothoracic surgeon, should have the decisive role in determining whether a patient could be treated with TAVI or SAVR.

, , ,
doi.org/10.4244/EIJV8I2A40, hdl.handle.net/1765/74949
EuroIntervention
Department of Cardio-Thoracic Surgery

van Mieghem, N., Head, S., van der Boon, R., Piazza, N., de Jaegere, P., Carrel, T., … Serruys, P. (2012). The SURTAVI model: Proposal for a pragmatic risk stratification for patients with severe aortic stenosis. EuroIntervention (Vol. 8, pp. 258–266). doi:10.4244/EIJV8I2A40